Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate
In type 2 diabetes, Hp levels differ by Hp phenotype and are decreased by fenofibrate in all phenotypes, but the effect is diminished in Hp 2-2.
Authors
- Hayden K. Young
- Rachel O’Connell (ORCID: https://orcid.org/0000-0002-8593-9767)
- ANTHONY C. KEECH (ORCID: https://orcid.org/0000-0002-9426-9136)
- Timothy J. Lyons (ORCID: https://orcid.org/0000-0003-2106-1622)
- Andrzej S. Januszewski (ORCID: https://orcid.org/0000-0003-0995-4524)
- Kwok Leung Ong (ORCID: https://orcid.org/0000-0001-7229-7614)
- C. Kelly (ORCID: https://orcid.org/0000-0002-8215-4796)
- Dessi P. Zaharieva (ORCID: https://orcid.org/0000-0002-9374-8469)
- DAVID R. SULLIVAN (ORCID: https://orcid.org/0000-0003-3085-5627)
- Alicia J. Jenkins (ORCID: https://orcid.org/0000-0003-0583-3717)
- Russell Scott (ORCID: https://orcid.org/0000-0002-2107-6480)
- Liping Li (ORCID: https://orcid.org/0000-0001-7396-1310)
Institutions
- Queen's University Belfast (GB)
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Medical University of South Carolina (US)
- The University of Melbourne (AU)
- Government of Western Australia Department of Health (AU)
- Blue Cross and Blue Shield of North Carolina Foundation (US)
- Clinical Trials New Zealand (NZ)
- Christchurch Clinical Studies Trust (NZ)
- Stanford Medicine (US)
- National Health and Medical Research Council (AU)
- Stanford University (US)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1111/jdi.14290
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Diabetes Australia
- Diabetesliitto
- Medical Research Council
- National Health and Medical Research Council